Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165409 · ClinicalTrials.gov registry record
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,828
- Enrollment target
NCT03165409 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,828 participants.
The verdict
NCT03165409 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,828 participants
- Enrollment target
Study Summary
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,828 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2017-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03165409
The ClinicalTrials.gov registry entry for NCT03165409 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,828 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03165409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03165409 about?
NCT03165409 is a clinical study titled "Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread". This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
What is the current status of trial NCT03165409?
This trial is currently completed. The enrollment target is 1,828 participants. The study started on 2017-02-27. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT03165409?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03165409?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.